Research map: TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10

Back to the article

Papers in this map

  1. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence · Rebecca Alexandra Dent · 2007 · 5230 citations · Cited by this paper
  2. Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study · 2026 · Related
  3. Triple-Negative Breast Cancer · William David Foulkes · 2010 · 4282 citations · Cited by this paper
  4. Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences · 2026 · Related
  5. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer · Alessandra Gennari · 2021 · 1443 citations · Cited by this paper
  6. Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice · 2026 · Related
  7. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer · Javier Cortés · 2022 · 1196 citations · Cited by this paper
  8. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary · 2026 · Related
  9. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network · Nancy U. Lin · 2012 · 725 citations · Cited by this paper
  10. Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience · 2026 · Related
  11. Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients · Gloria Joan Morris · 2007 · 615 citations · Cited by this paper
  12. IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma · 2026 · Related
  13. Trop2 and its overexpression in cancers: regulation and clinical/ therapeutic implications · Anna Shvartsur · 2014 · 410 citations · Cited by this paper
  14. Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia · 2026 · Related
  15. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives · Eleonora Nicolò · 2022 · 231 citations · Cited by this paper
  16. Sacituzumab govitecan in colorectal cancer: clinical evidence and future directions · 2026 · Related
  17. Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis · Ping Zeng · 2016 · 169 citations · Cited by this paper
  18. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors · Qing Wei · 2024 · 165 citations · Cited by this paper
  19. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132 · Yezhe Cheng · 2022 · 99 citations · Cited by this paper
  20. Trop-2 as a Therapeutic Target in Breast Cancer · Elizabeth A. Sakach · 2022 · 90 citations · Cited by this paper
  21. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer · Javier Cortés · 2025 · 86 citations · Cited by this paper
  22. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer · Yeonjin Jeon · 2022 · 71 citations · Cited by this paper
  23. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial · Yongmei Yin · 2025 · 62 citations · Cited by this paper
  24. Real-World Effectiveness Outcomes in Patients Diagnosed with Metastatic Triple-Negative Breast Cancer · Karen E Skinner · 2020 · 55 citations · Cited by this paper
  25. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). · Yasushi Goto · 2023 · 54 citations · Cited by this paper
  26. Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. · Binghe Xu · 2024 · 49 citations · Cited by this paper
  27. Unmet need for previously untreated metastatic triple-negative breast cancer: a real-world study of patients diagnosed from 2011 to 2022 in the United States · Kevin Punie · 2025 · 33 citations · Cited by this paper
  28. New Treatment Approaches for Triple-Negative Breast Cancer · Fauzia Riaz · 2025 · 29 citations · Cited by this paper
  29. 181O Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC) · Peter E. Schmid · 2024 · 22 citations · Cited by this paper
  30. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. · Yongmei Yin · 2025 · 12 citations · Cited by this paper
  31. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer · Alan Celik · 2023 · 12 citations · Cited by this paper
  32. Harnessing the PD-1 Pathway in Renal Cell Carcinoma: Current Evidence and Future Directions · Abhishek Dutt Tripathi · 2014 · 9 citations · Cited by this paper
  33. Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study. · Wenfeng Fang · 2025 · 6 citations · Cited by this paper
  34. Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study · P. Schmid · 2026 · 3 citations · Cited by this paper
  35. Untitled · Cited by this paper

Source: OpenAlex (CC0)